Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

NCT01031628 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Lack of feasibility secondary to slow accrual

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: Imatinib mesylate
DRUG: Imatinib mesylate
DRUG: Imatinib mesylate

Sponsor

Sarcoma Alliance for Research through Collaboration

Collaborators

[object Object]